Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • pomaglumetad methionil

    - PMLiVE

    AbbVie and ADARx enter multi-billion dollar partnership to develop siRNA therapies

    The companies will focus on developing therapeutics across neuroscience, immunology and oncology

    - PMLiVE

    J&J expands neuroscience capabilities with $14.6bn Intra-Cellular acquisition

    The deal gives the company access to a range of central nervous system disorder drugs

    - PMLiVE

    Novartis and Schrödinger to advance drug candidates in deal worth over $2.4bn

    The companies will advance therapeutics for undisclosed targets in Novartis’ core areas

    - PMLiVE

    AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition

    The deal includes a candidate in phase 1 development for Alzheimer's disease

    Bayer symbol

    Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

    The companies will advance small molecule therapeutics against a new class of targets for cancer

    - PMLiVE

    Takeda and Degron enter molecular glue degrader partnership worth over $1.2bn

    The companies will focus on targets in oncology, neuroscience and inflammation

    - PMLiVE

    Novartis acquires DTx Pharma in deal worth up to $1bn

    The agreement gives Novartis access to three preclinical neuroscience programmes

    Data-Driven Approaches for Neurorecovery

    Yotam Drechsler (Co-founder/CEO) and Yaron Segal (Co-founder/CINO) from BrainQ Technologies dives into the roles of Brain-Computer Interface technologies and electrophysiology measurements in aiding neurorecovery, the role of AI and machine...

    Impetus Digital

    - PMLiVE

    Lilly restructures in preparation for Alzheimer’s drug launch

    As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

    - PMLiVE

    Lilly restructures in preparation for Alzheimer’s drug launch

    As excitement builds around its potential Alzheimer’s drug, donanemab, Lilly has created a new neuroscience business unit, Lilly Neuroscience, to shepherd the company’s portfolio in pain and neurodegeneration

    - PMLiVE

    Numbers, navigation, and narratives: digital storytelling in medical communications

    Science and storytelling aren’t often seen as compatible. One is based on cold, hard facts, while the other is synonymous with improvisation and theater. However, when done well, storytelling can...

    Avalere Health

    Therapeutic VR for Managing Pain & Improving Patient Outcomes

    Ramsay Brown, CEO and Founder of Quol, delves into several different HealthTech topics, including the concept of VR therapeutics and the importance of incorporating behavioral science and neuroscience into VR solutions, as...

    Impetus Digital

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links